Wednesday, November 13, 2024

E-CIGARETTES (VAPING) AND UVEITIS

 A new study in Ophthalmology found that there was an elevated risk of uveitis among patients who vape. 

The results showed that e-cigarette users demonstrated a heightened risk of developing uveitis when compared to non-users. 

Traditional cigarette use was also found to increase uveitis risk, but not as significantly as e-cigarette use. 


Tuesday, November 12, 2024

LOSARTAN FOR PREVENTION OF CORNEAL SCARRING

 This is an excellent review of the use of topical Losartan to minimize corneal scarring in conditions that cause corneal damage.  It is not yet available but can be formulated. 

Thursday, October 31, 2024

LOW BMI ASSOCIATED WITH GLAUCOMA PROGRESSION

This  study in the American Journal of Ophthalmology concludes:


In this African ancestry cohort, low BMI was associated with increased POAG risk. POAG cases with low BMI were more likely to have larger cup-to-disc ratios, worse visual acuity, and faster functional progression, indicating more severe glaucoma.

Wednesday, October 30, 2024

SLIGHT INCREASE IN NAION WITH SEMIGLUTIDE INJECTIONS

 This report on a study demonstrates that there is a slight increase (3% ) in non arteritic ischemic optic neuropathy in patients receiving semiglutide injections.  The increase is slightly higher in males than females. 


Tuesday, October 29, 2024

VITAMIN D AND MACULAR DEGENERATION

 This is a report on a study that suggests that increased vitamin D levels, such as that associated with increased sun exposure, may be correlated with increased risk for macular degeneration.  

Monday, October 28, 2024

SUPPLEMENTS AND MACULAR DEGENERATION

The researchers found that among patients aged 50 and up, supplement use was associated with lower rates of developing or AMD or progressing AMD when compared with age- and sex-matched patients with no history of supplement use. Tumeric is mentioned in the title of this report. 

Thursday, October 03, 2024

Alpha Agonists in Glaucoma Patients may Increase the Risk of Alzheimer's Disease.

 From Review of Optometry:


Researchers in Taiwan designed a nationwide large study to investigate the association between


Alzheimer's Disease (AD) and different classes of topical glaucoma medications. They determined that using topical alpha-2 adrenergic agonists should be undertaken judiciously, especially in middle-aged and older populations. Their findings also indicated glaucoma may increase the risk of AD regardless of glaucoma subtype.

“Our observations indicating that alpha-2 adrenergic agonists potentially confer an increased risk of developing AD when compared to beta-blockers 

Irrespective of the type of glaucoma, individuals with glaucoma had a significantly higher risk of AD compared with those without glaucoma.

“Eyecare practitioners and neurologists need to be aware of the potentially higher risk of AD development associated with alpha-2 adrenergic agonists compared with beta-blockers among glaucoma patients,” they concluded in their paper for the journal.

Thursday, September 26, 2024

HIGH HDL MAY BE A RISK FACTOR FOR DEMENTIA AND GLAUCOMA

 “Good cholesterol” has been praised for its association with reduced cardiovascular disease risk, but new evidence suggests that elevated levels of this high-density lipoprotein cholesterol (HDL-C) may be harmful to the central nervous system. Serum lipid studies have reported associations between HDL-C and increased risk of dementia, and other associations with IOP and glaucoma have also been reported.

the study revealed an association between HDL-C levels and neurodegenerative diseases, suggesting that elevated HDL-C may serve as a novel risk factor for conditions such as dementia."


- Review of Optometry

Tuesday, September 10, 2024

Central Treatment Zone, CRT, and Myopia Control

 According to this report, CRT lenses with a smaller treatment zone are better for myopic control.  


Monday, September 09, 2024

PSORIASIS AND MACULAR DEGENERATION

 This report in Review of Optometry demonstrates a relationship between psoriasis and neovascularization in age-related macular degeneration.  


Friday, August 16, 2024

ONCE WEEKLY 1% ATROPHY

 According to this study,  1% Atropine administered once per week may be adequate to slow myopia progression.  It suggests that some patients may not respond as well, and that this can be determined within the first 2 months of initiation of treatment.  


Monday, August 12, 2024

LOWER BLOOD PRESSURE INCREASES GLAUCOMA PROGRESSION IN SOME PATIENTS

This report discussed this study: 

"Researchers wanted to examine the relationship between systemic arterial blood pressure and the rate of change in standard automated perimetry (SAP) in glaucomatous eyes and glaucoma suspects. 

"Each 10mm HG lower in 24-hour average mean arterial pressure and systolic BP were linked with -0.17dB/year and -0.14dB/year faster rates of mean deviation loss. Mean deviation loss was also associated with lower mean systolic BP during follow-up.

"Glaucomatous eyes with progression at low IOP levels may benefit from 24-hour blood pressure monitoring."



Monday, July 29, 2024

VITAMIN D AND DRY EYES

Patients suffering from dry eye may find relief with vitamin D supplementation, according to a review and meta-analysis published recently in Contact Lens and Anterior Eye. Researchers from China explained in their paper that vitamin D “deficiency exacerbates the ocular inflammatory response in patients with chronic dry eye.  They added that deficient levels of this vitamin may also affect nerve fibers, resulting in worse symptoms of ocular pain or foreign body sensation.

Upon analysis, the researchers found that vitamin D supplementation significantly improved tear production by Schirmer testing and tear film stability by tear break-up time and reduced lid hyperemia, and OSDI scores.